BIO
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

991
Loading...
Loading...
News
all
press releases
Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?
BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Earnings Preview: Bio-Rad Laboratories (BIO) Q2 Earnings Expected to Decline
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
BIO surges 4% as the Stilla acquisition fuels the launch of four ddPCR systems, expanding to 400K+ assay offerings.
Zacks·3mo ago
News Placeholder
New Strong Sell Stocks for July 10th
BIO, DECK and ELUXY have been added to the Zacks Rank #5 (Strong Sell) List on July 10, 2025.
Zacks·3mo ago
News Placeholder
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
Zacks·4mo ago
News Placeholder
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
Zacks·5mo ago
News Placeholder
Is Thermo Fisher Scientific Stock Underperforming the S&P 500?
Although Thermo Fisher Scientific has lagged behind the broader S&P 500 index over the past year, analysts remain confident in its long-term growth prospects.
barchart.com·7mo ago
News Placeholder
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year...
Business Wire·8mo ago
News Placeholder
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to...
Business Wire·8mo ago
News Placeholder
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year of...
Business Wire·8mo ago

Latest BIO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.